Materialise (MTLS) Panoramica del titolo
Materialise NV fornisce strumenti software di produzione additiva e medicale e servizi di stampa 3D nelle Americhe, in Europa, in Africa e nell'Asia-Pacifico. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per MTLS dai nostri controlli di rischio.
MTLS Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Materialise NV
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$7.46 |
| Massimo di 52 settimane | US$7.67 |
| Minimo di 52 settimane | US$4.78 |
| Beta | 1.36 |
| Variazione di 1 mese | 8.91% |
| Variazione a 3 mesi | 12.18% |
| Variazione di 1 anno | 47.14% |
| Variazione a 3 anni | 22.70% |
| Variazione a 5 anni | -67.49% |
| Variazione dall'IPO | -37.31% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Sep 03
MTLS: Reaffirmed 2026 Guidance Will Support Higher Profitability Expectations
Analysts have modestly raised their price target on Materialise to about $8.06 from about $6.81, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News for Materialise Materialise NV recorded impairment charges of €689,000 in the second quarter of 2026 related to tangible and intangible assets of RapidFit NV and Eyewear, following the transfer of these assets to their respective management teams.Seeking Alpha • Aug 31
Materialise: A High-Margin Medical Business Hiding In Plain Sight
Summary Materialise’s Medical continues to deliver double-digit growth and strong margins and is increasingly underpinning the company’s value. The Manufacturing segment is recovering, with aerospace strength offsetting weak prototyping demand and creating significant potential for margin expansion. Software is now an uncertainty, as recurring revenue growth has stalled despite Materialise's transition toward subscriptions and the introduction of new CO-AM products. The valuation remains attractive if Materialise can achieve even modest revenue growth and margin expansion over the next few years. Read the full article on Seeking AlphaArticolo di analisi • Aug 30
Materialise NV (NASDAQ:MTLS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.92
It's been a good week for Materialise NV ( NASDAQ:MTLS ) shareholders, because the company has just released its latest...Recent updates
Aggiornamento narrativa • Sep 03
MTLS: Reaffirmed 2026 Guidance Will Support Higher Profitability Expectations
Analysts have modestly raised their price target on Materialise to about $8.06 from about $6.81, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News for Materialise Materialise NV recorded impairment charges of €689,000 in the second quarter of 2026 related to tangible and intangible assets of RapidFit NV and Eyewear, following the transfer of these assets to their respective management teams.Seeking Alpha • Aug 31
Materialise: A High-Margin Medical Business Hiding In Plain Sight
Summary Materialise’s Medical continues to deliver double-digit growth and strong margins and is increasingly underpinning the company’s value. The Manufacturing segment is recovering, with aerospace strength offsetting weak prototyping demand and creating significant potential for margin expansion. Software is now an uncertainty, as recurring revenue growth has stalled despite Materialise's transition toward subscriptions and the introduction of new CO-AM products. The valuation remains attractive if Materialise can achieve even modest revenue growth and margin expansion over the next few years. Read the full article on Seeking AlphaArticolo di analisi • Aug 30
Materialise NV (NASDAQ:MTLS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.92
It's been a good week for Materialise NV ( NASDAQ:MTLS ) shareholders, because the company has just released its latest...
Nuova narrativa • Jun 01
Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability
Catalysts About Materialise Materialise provides 3D printing software and services, with a particular focus on medical applications and industrial manufacturing. What are the underlying business or industry changes driving this perspective?Nuova narrativa • May 17
Cloud Software And Medical Constraints Will Pressure 3D Printing Adoption Yet Offer Gradual Upside
Catalysts About Materialise Materialise provides software and manufacturing solutions for 3D printing, with a particular focus on medical applications, industrial production and related services. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Nov 05
Materialise's (NASDAQ:MTLS) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market rallied behind Materialise NV's ( NASDAQ:MTLS ) stock, leading do a rise in the share price after its recent...Articolo di analisi • Oct 06
Materialise NV's (NASDAQ:MTLS) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 54.9x Materialise NV ( NASDAQ:MTLS ) may be sending very bearish signals...Articolo di analisi • Jul 27
Analyst Estimates: Here's What Brokers Think Of Materialise NV (NASDAQ:MTLS) After Its Second-Quarter Report
Shareholders might have noticed that Materialise NV ( NASDAQ:MTLS ) filed its quarterly result this time last week. The...Articolo di analisi • Jul 25
Materialise (NASDAQ:MTLS) Is Looking To Continue Growing Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Articolo di analisi • May 04
After Leaping 28% Materialise NV (NASDAQ:MTLS) Shares Are Not Flying Under The Radar
Those holding Materialise NV ( NASDAQ:MTLS ) shares would be relieved that the share price has rebounded 28% in the...Seeking Alpha • Feb 24
Materialise: Manufacturing Headwinds Are A Distraction
Summary Materialise's share price dropped significantly after the company reported poor Q4 earnings, which were driven by European automotive market weakness. Despite recent challenges, Materialise's Medical segment continues to perform well and the transition of the Software segment to a subscription model is progressing. The Medical and Software segments are Materialise's primary value drivers and more than justify the company's current valuation. Issues with the Manufacturing segment may need to be resolved before the stock moves higher though. Read the full article on Seeking AlphaArticolo di analisi • Feb 13
Materialise NV's (NASDAQ:MTLS) P/E Is Still On The Mark Following 26% Share Price Bounce
Materialise NV ( NASDAQ:MTLS ) shareholders have had their patience rewarded with a 26% share price jump in the last...
Nuova narrativa • Feb 09
Launch Of Mimics Flow And ACTech Expansion Will Advance Personalized Medicine
Focus on personalized medical solutions and enhanced platforms could drive revenue growth and improve operational efficiencies and net margins.Articolo di analisi • Jan 31
Materialise NV (NASDAQ:MTLS) Shares Could Be 28% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Materialise fair value estimate is US$6.77 Materialise is...Articolo di analisi • Jan 07
These 4 Measures Indicate That Materialise (NASDAQ:MTLS) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Nov 07
Materialise NV's (NASDAQ:MTLS) 27% Jump Shows Its Popularity With Investors
Materialise NV ( NASDAQ:MTLS ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Seeking Alpha • Nov 04
Materialise: Strong Q3 Results Despite Ongoing Market Headwinds
Summary Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue. Despite the stock moving higher in recent weeks, Materialise remains deeply undervalued. Read the full article on Seeking AlphaArticolo di analisi • Nov 01
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) recently posted some strong earnings, and the market responded positively. We did some...Seeking Alpha • Oct 25
Materialise: Medical Business Unit Is The Hidden Value
Summary Materialise NV is a Belgian additive manufacturing company, showing a 14.18% CAGR in its Medical segment from FY18 to FY23. Despite mixed results in other segments, Materialise maintains profitability with positive FCF and a strong balance sheet, supported by €63 million in net cash. The company's strategic positioning in high-value sectors and steady growth, combined with a net cash position and positive FCF, highlight its upside potential. DCF analysis suggests Materialise is undervalued by 35-40%, justifying a "buy" rating due to its innovative edge and expanding market in healthcare. Read the full article on Seeking AlphaArticolo di analisi • Oct 25
Is There Now An Opportunity In Materialise NV (NASDAQ:MTLS)?
While Materialise NV ( NASDAQ:MTLS ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Seeking Alpha • Aug 01
Materialise Stock: Nearing An Inflection Point (Rating Upgrade)
Summary Materialise NV continues to face headwinds from soft prototyping demand and muted 3D printer sales. Despite this, Materialise reported solid Q2 results, with growth improving sharply. Recent acquisitions, new software launches, and expanded manufacturing capacity are expected to drive growth going forward. While Materialise's share price has moved higher recently, the prospect of solid growth and significantly higher margins are not priced into the stock. Read the full article on Seeking AlphaArticolo di analisi • Aug 01
The Return Trends At Materialise (NASDAQ:MTLS) Look Promising
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Seeking Alpha • Apr 26
Materialise Q1: Progress Against Headwinds
Summary Materialise NV faces a challenging demand environment and is transitioning to a cloud-based SaaS business model, impacting its financial performance. The software business is progressing slowly, while the medical business continues to perform well. The manufacturing business is struggling, but the startup of the expanded ACTech facility later in the year could change this. Macro headwinds and ongoing investments probably limit near-term upside. Longer term, Materialise appears deeply undervalued. Read the full article on Seeking AlphaArticolo di analisi • Apr 19
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) just reported healthy earnings but the stock price didn't move much. Investors are...Seeking Alpha • Feb 26
Materialise: Upside From A Transition To Profitability
Summary The demand environment continues to weigh on Materialise's business, although the Medical segment remains a standout, with strong growth and improving margins. The adoption of robotics in joint replacement surgeries poses a threat to Materialise's medical business, though. Investments in the CO-AM platform and the ACTech facility expansion should begin to pay off in 2024, supporting growth and Materialise's competitive position. Given Materialise's relatively low valuation and the potential for solid growth and improving margins, Materialise's stock should do well over the next 1-2 years. Read the full article on Seeking AlphaArticolo di analisi • Feb 23
Does Materialise (NASDAQ:MTLS) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 31
Materialise NV: Consolidation And New Developments To Emerge As A Rising Star In The Additive Manufacturing Industry
Summary Materialise NV currently exhibits better growth, margins and fundamentals than its main competitors, positioning itself well in an industry that is estimated to grow at a CAGR of 16% until 2032; The medical business unit (c.a. 38.5% of total revenues in 9M23) continues to achieve double-digit growth, with the appointment of the new CEO to focus strongly on this segment; Both the analysis of multiples and DCF here presented show that the current share valuation is 40-45% below its fundamental value. Read the full article on Seeking AlphaArticolo di analisi • Jun 14
Here's Why Materialise (NASDAQ:MTLS) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • May 23
Returns On Capital At Materialise (NASDAQ:MTLS) Paint A Concerning Picture
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Rendimenti per gli azionisti
| MTLS | US Software | US Mercato | |
|---|---|---|---|
| 7D | 5.5% | -0.7% | -0.2% |
| 1Y | 47.1% | -9.0% | 14.8% |
Ritorno vs Industria: MTLS ha superato il US Software che ha restituito -9 % nell'ultimo anno.
Rendimento vs Mercato: MTLS ha superato il mercato US che ha restituito 14.8 % nell'ultimo anno.
Volatilità dei prezzi
| MTLS volatility | |
|---|---|
| MTLS Average Weekly Movement | 5.7% |
| Software Industry Average Movement | 9.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: MTLS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di MTLS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1990 | 2,556 | Brigitte de Vet-Veithen | www.materialise.com |
Materialise NV fornisce strumenti software di produzione additiva e medicale e servizi di stampa 3D nelle Americhe, in Europa, in Africa e nell'Asia-Pacifico. L'azienda opera attraverso tre segmenti: Materialise Software, Materialise Medical e Materialise Manufacturing. Il segmento Materialise Software offre software proprietario attraverso programmi e piattaforme che consentono e migliorano la funzionalità delle stampanti 3D e delle operazioni di stampa.
Materialise NV Riepilogo dei fondamenti
| MTLS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$437.43m |
| Utili (TTM) | US$15.36m |
| Ricavi(TTM) | US$317.25m |
28.1x
Rapporto P/E1.4x
Rapporto P/SMTLS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| MTLS Conto economico (TTM) | |
|---|---|
| Ricavi | €272.77m |
| Costo del fatturato | €116.66m |
| Profitto lordo | €156.12m |
| Altre spese | €142.91m |
| Utili | €13.21m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
Oct 28, 2026
| Utile per azione (EPS) | 0.23 |
| Margine lordo | 57.23% |
| Margine di profitto netto | 4.84% |
| Rapporto debito/patrimonio netto | 20.9% |
Come si è comportato MTLS nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/09 19:32 |
| Prezzo dell'azione a fine giornata | 2026/09/09 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Materialise NV è coperta da 11 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John Baliotti | Brean Capital Historical (Janney Montgomery) |
| Robert Burleson | Canaccord Genuity |
| Troy Jensen | Cantor Fitzgerald & Co. |